Only recently, the life science industry opened up to Research & Development (R&D) projects through public-private partnerships (PPPs). A logical evolution, since such approach allows to leverage impact and possible breakthroughs in cases it is the only way to move forward.
A clear example on how PPPs benefit the R&D field is the Innovative Medicines Initiative (IMI), a partnership between the European Union and the European pharmaceutical industry to facilitate research collaboration for the development of medicines, especially in areas of unmet medical need. More than 100 projects have benefited from this unique set-up, leading to over 3800 publications.
Many of these projects are in the field of Alzheimer's Disease, accounting for over 250 million euros. After many years of clinical trial failure in this field, pharmaceutical companies are now working together with the public sector, imaging companies and patient organizations to set up game-changing projects that approach Alzheimer's Disease from a different perspective.
An example of this is the European Prevention of Alzheimer's Dementia (EPAD) project, an IMI project with 39 institutions closely collaborating together to create a novel platform to run phase II studies for secondary prevention of Alzheimer's Dementia.
READ THE FULL ARTICLE (Source: PharmaBoardRoom)